1GLOBAL
Kuwait-based low-cost airline Jazeera Airways has partnered with London headquartered Telco 1GLOBAL to become the first airline in the MENA region to launch its own travel eSIM offering. The collaboration will enable Jazeera passengers to communicate cost-effectively and avoid expensive roaming costs when travelling. At the same time, it will serve to strengthen Jazeera Airways´ customer loyalty and satisfaction, while boosting ancillary revenues.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240122511628/en/
Yousef Al Qatami, Chief of Staff at 1GLOBAL. (Source: 1GLOBAL)
Leveraging the power of eSIM
Through the partnership 1GLOBAL will integrate its consumer eSIM technology into Jazeera Airlines' service offering. The process will begin with the implementation of a Jazeera branded QR code and web-based solution, followed by a full-fledged integration into the Jazeera Airways app. The white label solution allows Jazeera to offer eSIM services while maintaining the airlines own look and feel.
Andrew Ward, Vice President Marketing & Customer Experience at Jazeera Airways, says: "We are delighted to be able to offer the 1GLOBAL service to our passengers. We are always looking for ways to reduce travel costs and the 1GLOBAL eSIM offers low call rates for travellers across the Jazeera network."
A benefit for both the airline and its passengers
The roaming solution will be marketed through various communication channels including social media, in-flight magazines, email confirmations and promotional material in airport terminals. The partnership offers benefits for both travellers and Jazeera Airways. By activating the 1GLOBAL roaming eSIM, travellers will be able to stay connected more cost effectively than if they were using their standard roaming plan. They will also have access to high quality 5G & 4G coverage in almost all countries with plenty of flexible tariff options to choose from. Jazeera Airways on the other hand hopes to increase customer loyalty by providing this value-added service. This initiative not only distinguishes Jazeera Airways from its competitors through innovative offerings, but it also aims to increase revenue through ancillary services.
Yousef Al Qatami, Chief of Staff at 1GLOBAL, emphasises: "We are very proud to have supported the Jazeera Airways team in being the first airline in the MENA region to launch an eSIM offering. We are confident in the region's growth trajectory and hope to bring the benefits of eSIM to more local businesses and customers."
About Jazeera Airways
Jazeera Airways operates commercial and cargo flights out of its Jazeera Terminal T5 at Kuwait International Airport. The airline flies to over 64 popular destinations across the Middle East, Central and South Asia, Africa and Europe comprising high-demand business, leisure, religious and weekend destinations.
About 1GLOBAL
Founded in 2022, 1GLOBAL acquired a group of telco assets operational since 2006, including an internationally recognized GSMA-accredited global mobile network. Headquartered in London with our R&D hub in Lisbon, we have grown to over 400 employees across 12 countries and have been granted the status of fully regulated MVNO in 9 of them.
As innovators in eSIM-based GSM mobile services, 1GLOBAL caters to both businesses and individuals with products including mobile call and SMS recording services for businesses, remote SIM provisioning, IOT solutions, Telco-as-a-Service for travel companies, and affordable roaming for everyday consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122511628/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom